3,4-methylenedioxymethamphetamine (MDMA) assisted therapy for the treatment of social anxiety in autistic adults
DOI:
https://doi.org/10.33448/rsd-v13i4.44932Keywords:
MDMA; Autism; Social anxiety.Abstract
Autism spectrum disorder is a neurodevelopmental condition that causes deficits in an individual's interpersonal interaction and communication, which can lead to the development of social anxiety. The lack of an effective pharmacological treatment with reduced side effects has attracted researchers' attention to treatment with alternative approaches. 3,4-methylenedioxymethamphetamine (MDMA) is a synthesized active compound, found in Ecstasy, capable of producing a great sensation of affection and pro-social intentions, increasing the release of serotonin, dopamine and oxytocin, facilitating the process of social interaction. The objective of this article was to inform, through a bibliographic survey, about the history of clinical research with psychedelics, especially MDMA, its influence on the treatment of social anxiety in adults with autism spectrum disorder and to encourage future studies with these substances. A bibliographical review was carried out from 1986 to 2023 through Pubmed and SciELO. The historical context and pharmacology of MDMA were described, as well as its importance and interaction in the social anxiety of adults with autism. The mechanism of action was reported in order to justify the therapeutic possibilities associated with the use of MDMA. As a result, data on significant improvements in the symptoms of social anxiety in the study subjects were obtained, and its prescription was authorized in Australia for the treatment of Post-Traumatic Stress Disorder, becoming very promising in the search for an effective medication for the Treatment of social anxiety in people with autism spectrum disorder.
References
APA. (2013). DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5™ (5th ed.). American Psychiatric Publishing, Inc. https://doi.org/10.1176/appi.books.9780890425596
Australian Goverment. (2023). Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists. Department of Health and Aged Care, Therapeutic Goods Administration (TGA). https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists
Baumann, M. H., Wang, X., & Rothman, R. B. (2006). 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology, 189(4), 407–424. https://doi.org/10.1007/s00213-006-0322-6
Bedi, G., K. Luan Phan, Angstadt, M., & Harriet de Wit. (2009). Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacology, 207(1), 73–83. https://doi.org/10.1007/s00213-009-1635-z
Bejerot, S., Eriksson, J., & Mörtberg, E. (2014). Social anxiety in adult autism spectrum disorder. Psychiatry Research, 220(1-2), 705–707. https://doi.org/10.1016/j.psychres.2014.08.030
Capadócia, MC, Weiss, JA & Pepler, D. (2012) Experiências de bullying entre crianças e jovens com transtornos do espectro do autismo. J Autismo Dev Disord 42, 266–277. https://doi.org/10.1007/s10803-011-1241-x
Cordeiro, L. & Soares, C. B. (2019). Revisão de escopo: potencialidades para a síntese de metodologias utilizadas em pesquisa primária qualitativa. Bis. 20(2), 37-43. https://docs.bvsalud.org/biblioref/2019/10/1021863/bis-v20n2-sintese-de-evidencias-qualitativas-37-43.pdf
Danforth, Alicia Lynn (2013). Courage, connection, and clarity: A mixed-methods collective-case study of MDMA (ecstasy) experiences of autistic adults. Institute of Transpersonal Psychology ProQuest Dissertations Publishing. 3596826.
Danforth, A. L., Grob, C. S., Struble, C. M., Feduccia, A. A., Walker, N., Jerome, L., Berra Yazar‐Klosinski, & Emerson, A. (2018). Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology, 235(11), 3137–3148. https://doi.org/10.1007/s00213-018-5010-9
Danforth, Alicia Lynn (2019). Embracing Neurodiversity in Psychedelic Science: A Mixed-Methods Inquiry into the MDMA Experiences of Autistic Adults. Journal of Psychoactive Drugs, 51:2, 146-154, DOI: 10.1080/02791072.2019.1587116
Feduccia, A. A., Jerome, L., Berra Yazar‐Klosinski, Emerson, A., Mithoefer, M. C., & Doblin, R. (2019). Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline. Frontiers in Psychiatry, 10. https://doi.org/10.3389/fpsyt.2019.00650
Freudenmann, R. W., Florian Öxler, & Bernschneider-Reif, S. (2006). The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction, 101(9), 1241–1245. https://doi.org/10.1111/j.1360-0443.2006.01511.x
Grob, C. S., Poland, R. E., Chang, L., & Ernst, T. (1995). Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behavioural Brain Research, 73(1-2), 103–107. https://doi.org/10.1016/0166-4328(96)00078-2
Mayo‐Wilson, E., Dias, S., Ifigeneia Mavranezouli, Kew, K. M., Clark, D. M., Ades, A. E., & Pilling, S. (2014). Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. The Lancet Psychiatry, 1(5), 368–376. https://doi.org/10.1016/s2215-0366(14)70329-3
Niles, A. N., Burklund, L. J., Arch, J. J., Lieberman, M. D., Saxbe, D., & Craske, M. G. (2014). Cognitive Mediators of Treatment for Social Anxiety Disorder: Comparing Acceptance and Commitment Therapy and Cognitive-Behavioral Therapy. Behavior Therapy, 45(5), 664–677. https://doi.org/10.1016/j.beth.2014.04.006
Pollan, M. (2018). How to change your mind: what the new science of psychedelics teaches us about consciousness, dying, addiction, depression, and transcendence. Penguin Press.
Reardon, S. (2023). US could soon approve MDMA therapy — opening an era of psychedelic medicine. Nature, 616(7957), 428–430. https://doi.org/10.1038/d41586-023-01296-3
Thompson, M. R., Hunt, G. E., & McGregor, I. S. (2009). Neural correlates of MDMA (“Ecstasy”)-induced social interaction in rats. Social Neuroscience, 4(1), 60–72. https://doi.org/10.1080/17470910802045042
Williams, T., Coenraad Hattingh, Kariuki, C. M., Tromp, S., A.J.L.M. van Balkom, Ipser, J., & Stein, D. J. (2017). Pharmacotherapy for social anxiety disorder (SAnD). The Cochrane Library, 2019(1). https://doi.org/10.1002/14651858.cd001206.pub3
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Jéssica de Sá Azevedo; Aline da Silva Guerra
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
